Alnylam unveils pricing strategy for second FDA-approved RNAi drug

Alnylam unveiled a performance-based and prevalence-based pricing strategy to mitigate risks to participating payers covering RNAi therapy Givlaari givosiran, which FDA approved more than two months ahead of schedule for adults with acute hepatic porphyria.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) plans to launch Givlaari by YE19 at an average annual list price of $575,000 and an average effective net price of $442,000 after discounts, President Barry Greene said on a call with investors Wednesday. ...